To say goodbye to 2022 and welcome in the new year, The Center for Biosimilars recaps the biggest news stories and milestones from the past 12 months as well as list of the top 5 podcast episodes of the year.
On this episode, we’re going to review the top stories and milestones to hit the biosimilar industry this year. From the launch of a generic lenalidomide, the FDA approval of a high-concentration adalimumab biosimilar, to the launch of the first ophthalmology biosimilar. We’re also going to be recommending our top 5 podcast episodes of the year so stick around to hear more about what 2022 has in store for biosimilars around the world.
Top 10 stories of the year:
Top 5 podcast episodes of the year: